Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here’s what to expect.

Gilead Sciences beat analysts’ revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and full-year revenue guidance meeting analysts’ expectations.

Is Gilead Sciences a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Gilead Sciences’s revenue to grow 3.8% year on year, improving from the 1.8% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Gilead Sciences rarely misses Wall Street’s revenue estimates.

Looking at Gilead Sciences’s peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 3.4%, beating analysts’ expectations by 12.1%, and Moderna reported revenues up 2.1%, topping estimates by 35.8%. Biogen traded up 1.1% following the results.

Read our full analysis of Biogen’s results here and Moderna’s results here.

Investors in the therapeutics segment have had steady hands going into earnings, with share prices flat over the last month. Gilead Sciences is up 1.5% during the same time and is heading into earnings with an average analyst price target of $157.15 (compared to the current share price of $131.40).

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.